Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
The present invention is directed to immunogenic conjugates comprised of a polymer, preferably a polysaccharide, with a covalently attached antigen and an agent for boosting a patient's immune response. The conjugates may be used in vaccines for a wide range of diseases.
1. An immunogenic composition comprising
a) a group B streptococcal polysaccharide of 1×10 3 -1×10 6 daltons;
b) HIV-1 env2-3 bound directly to said polysaccharide by a covalent bond; and
c) a booster that is either tetanus or diptheria toxoid bound directly to said polysaccharide by a covalent bond.
2. The immunogenic composition of claim 1 , further comprising HIV-1 gp120 covalently bound to said polysaccharide.
3. The immunogenic composition of claim 1 , wherein said HIV-1 env2-3 and said tetanus or diptheria toxoid are covalently bound to sialic acid groups on said group B streptococcal polysaccharide.
4. The immunogenic composition of claim 3 , further comprising HIV-1 gp120 covalently bound to sialic acid groups on said group B streptococcal polysaccharide.
5. The immunogenic composition of claim 4 , wherein said HIV-1 env2-3, said booster and said HIV-1 gp120 are joined to said sialic acid groups using an amination procedure.
6. The immunogenic composition of claim 4 , wherein said HIV-1 env2-3, said booster and said HIV-1 gp120 are joined to said sialic acid groups by a heterobifunctional or homobifunctional linker.
7. The immunogenic composition of claim 1 , wherein said booster is tetanus toxoid.
8. The immunogenic composition of claim 1 , wherein said polysaccharide has a molecular weight of 5000 to 500,000 daltons.
9. The immunogenic composition of claim 7 , further comprising HIV-1 gp120 covalently bound to said polysaccharide.
10. The immunogenic composition of claim 9 , wherein said polysaccharide has a molecular weight of 5000 to 500,000 daltons.
11. The immunogenic composition of claim 9 , wherein said HIV-1 env2-3 and said tetanus toxoid are covalently bound to sialic acid groups on said group B streptococcal polysaccharide.
12. The immunogenic composition of claim 11 , further comprising HIV-1 gp120 covalently bound to sialic acid groups on said group B streptococcal polysaccharide.
13. The immunogenic composition of claim 12 , wherein said HIV-1 env2-3, said booster and said HIV-1 gp120 are joined to said sialic acid groups using an amination procedure.
14. The immunogenic composition of claim 12 , wherein said HIV-1 env2-3, said booster and said HIV-1 gp120 are joined to said sialic acid groups by a heterobifunctional or homobifunctional linker.
15. An immunogenic composition consisting of:
a) a group B streptococcal polysaccharide of 1×10 3 -1×10 6 daltons;
b) HIV-1 env2-3 bound directly to said polysaccharide by a covalent bond;
c) a booster that is either tetanus or diptheria toxoid bound directly to said polysaccharide by a covalent bond.
d) HIV-1 gp120 bound directly to said polysaccharide by a covalent bond.
16. The immunogenic composition of claim 15 , wherein said HIV-1 env2-3, said booster and said HIV-1 gp120 are covalently bound to sialic acid groups on said group B streptococcal polysaccharide.
17. The immunogenic composition of claim 16 , wherein said HIV-1 env2-3, said booster and said HIV-1 gp120 are joined to said sialic acid groups using an amination procedure.
18. The immunogenic composition of claim 16 , wherein said HIV-1 env2-3,said booster and said HIV-1 gp120 are joined to said sialic acid groups by a heterobifunctional or homobifunctional linker.
19. The immunogenic composition of claim 16 , wherein said booster is tetanus toxoid.
20. The immunogenic composition of claim 19 , wherein said polysaccharide has a molecular weight of 5000 to 500,000 daltons.